Stryker Corporation management check
SYK · Health Care · Health Care Equipment · CEO Mr. Lobo
Filings as of
5 good · 2 to watch · 0 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2021 grew to $151, against $148 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.61 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good
What does the CEO cost owners?
0.7% of net income$21.4m of reported pay in fiscal 2025, against $3.2bn of net income.
- Watch
Do they own the stock?
Insiders are selling5 insiders sold $218.9m in the last six months and none bought. 6 of 36 sales ran on pre-arranged 10b5-1 plans.
- Watch
Are owners being diluted?
Share count growingDiluted shares changed +0.4% a year over the last three fiscal years. Stock-based pay was 1.0% of revenue in the latest year.
- Good
Is leadership stable?
7 leadership filings in 3 yearsCEO in the pay table: Mr. Lobo. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 52 | 26 | |
| Pay for performance | 81 | 85 | |
| CEO cost | 65 | 44 | |
| Skin in the game | — | — | 46 |
| Dilution | 45 | 68 | |
| Stable leadership | 90 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Equipment, by management score. Stryker Corporation is 14th of 60 in its sector.
- 115ABTAbbott Laboratories75
- 149SYKStryker Corporation72
- 156ISRGIntuitive Surgical72
- 188IDXXIdexx Laboratories69
- 192BSXBoston Scientific69
- 246RVTYRevvity64
- 256GEHCGE HealthCare64
- 294RMDResMed62
- 321STESteris60
- 353BDXBecton Dickinson58
Pay versus performance
From the proxy statement filed March 23, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Lobo | $21.4m | $24.8m | $4.6m | $151 | $148 | $3.2bn |
| 2024 | — | $22.0m | $48.2m | $6.4m | $153 | $129 | $3.0bn |
| 2023 | — | $20.8m | $42.5m | $6.1m | $126 | $126 | $3.2bn |
| 2022 | — | $18.6m | $11.4m | $5.2m | $102 | $124 | $2.4bn |
| 2021 | — | $16.4m | $27.8m | $5.8m | $110 | $126 | $2.0bn |
The board says pay is tied most to reported net sales growth. Its other key measures: Reported net sales growth, Constant currency sales, Adjusted net earnings per diluted share growth, Adjusted operating income, Adjusted operating income margin.
Insiders and the CEO's stake
5 insiders sold $218.9m in the last six months and none bought. 6 of 36 sales ran on pre-arranged 10b5-1 plans.
- SoldRonda E StrykerDirector$214.6mAug 19, 2026
- SoldM Kathryn FinkVP, Chief HR Officer$2.5mMay 11, 2026
- SoldRobert S FletcherVP, Chief Legal Officer · 10b5-1 plan$1.4mMay 28, 2026
- SoldDebra KingSee Remarks$278kAug 18, 2026
Leadership and governance on file
- Oct 6, 2026Leadership change8-K 5.02
- May 20, 2026Leadership change8-K 5.02
- Dec 4, 2025Leadership change8-K 5.02
- May 13, 2025Leadership change8-K 5.02
- Feb 10, 2025Leadership change8-K 5.02
- Jan 28, 2025Leadership change8-K 5.02
- Dec 8, 2023Leadership change8-K 5.02
Latest shareholder vote results: May 8, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $5.6bn returned to owners in buybacks and dividends, 41% of net income, and $1.0bn of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.1bn | $18.4bn | $20.5bn | $22.6bn | $25.1bn |
| Net income | $2.0bn | $2.4bn | $3.2bn | $3.0bn | $3.2bn |
| Stock-based pay | $171.0m | $168.0m | $205.0m | $229.0m | $243.0m |
| Buybacks | $0 | — | — | — | — |
| Dividends | $950.0m | $1.1bn | $1.1bn | $1.2bn | $1.3bn |
| Diluted shares | 382m | 382m | 384m | 386m | 387m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.